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Background-—Abnormal diurnal blood pressure (BP), including nondipping patterns, assessed using ambulatory BP monitoring,
have been associated with increased cardiovascular risk among white and Asian adults. We examined the associations of BP
dipping patterns (dipping, nondipping, and reverse dipping) with cardiovascular target organ damage (left ventricular mass index
and left ventricular hypertrophy), among participants from the Jackson Heart Study, an exclusively black population–based
cohort.
Methods and Results-—Analyses included 1015 participants who completed ambulatory BP monitoring and had echocardiography
data from the baseline visit. Participants were categorized based on the nighttime to daytime systolic BP ratio into 3 patterns:
dipping pattern (≤0.90), nondipping pattern (>0.90 to ≤1.00), and reverse dipping pattern (>1.00). The prevalence of dipping,
nondipping, and reverse dipping patterns was 33.6%, 48.2%, and 18.2%, respectively. In a fully adjusted model, which included
antihypertensive medication use and clinic and daytime systolic BP, the mean differences in left ventricular mass index between
reverse dipping pattern versus dipping pattern was 8.32.1 g/m2 (P<0.001) and between nondipping pattern versus dipping
pattern was 1.01.6 g/m2 (P=0.536). Compared with participants with a dipping pattern, the prevalence ratio for having left
ventricular hypertrophy was 1.65 (95% CI, 1.05–2.58) and 0.96 (95% CI, 0.63–1.97) for those with a reverse dipping pattern and
nondipping pattern, respectively.
Conclusions-—In this population-based study of blacks, a reverse dipping pattern was associated with increased left ventricular mass
index and a higher prevalence of left ventricular hypertrophy. Identification of a reverse dipping pattern on ambulatory BP monitoring
may help identify black at increased risk for cardiovascular target organ damage. ( J Am Heart Assoc. 2017;6:e004847. DOI: 10.
1161/JAHA.116.004847.)
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I n healthy adults, blood pressure (BP) is characterized by acircadian pattern during a 24-hour period with levels that
are normally highest while awake and fall during sleep.1
Ambulatory BP monitoring (ABPM) can be used to assess the
circadian pattern of BP.1,2 Based on the nighttime to daytime
systolic BP (SBP) ratio, individuals can be categorized by
dipping status into nondipping BP status (SBP ratio >0.90) or
dipping BP status (SBP ratio ≤0.90).3 However, in some
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individuals there may be an excess rise or fall in nighttime BP
relative to daytime BP.4,5 Some investigators6 have proposed
that dipping status should be further categorized into 4
dipping patterns4: extreme dipping pattern (SBP ratio ≤0.80),
dipping pattern (0.80< SBP ratio ≤0.90), nondipping pattern
(0.90< SBP ratio ≤1.00), and reverse dipping pattern (SBP
ratio >1.00), as these patterns may provide more prognostic
information than dipping dichotomized as nondipping BP or
dipping BP status.
Prior studies have demonstrated that nondipping and
reverse dipping patterns are associated with increased
mortality and cardiovascular events when compared with a
dipping pattern.5,7–12 Also, an association between nondipping
BP status and subclinical target organ damage, including left
ventricular mass index (LVMI) and left ventricular hypertrophy
(LVH), has been previously demonstrated.13–16 However, less
is known about the association between reverse dipping
pattern with LVMI or LVH. The prior studies17,18 that have
examined the association between reverse dipping patterns
and LVMI have provided conflicting results. These studies were
conducted mostly among adults who had untreated hyper-
tension. Neither study17,18 included blacks, who are known to
have a high prevalence of hypertension and hypertension-
related cardiovascular target organ damage,19–21 including
increased LVMI and a higher prevalence of LVH compared with
whites.22 In addition, blacks are also more likely to have
nondipping BP and higher nighttime BP compared with
whites.23,24
In the current study, we examined the association of BP
dipping patterns with LVMI and LVH among participants in the
Jackson Heart Study (JHS), a large population-based cohort
study comprised exclusively of blacks. We examined these
associations for the overall population and for participants
taking and not taking antihypertensive medication, separately.
In secondary analyses, we also examined the associations of
nighttime BP with LVMI and LVH.
Methods
Study Population
The JHS enrolled 5306 noninstitutionalized blacks, 21 years
and older, between 2000 and 2004 from the Atherosclerosis
Risk in the Community (ARIC) site in Jackson, MS, and a
representative sample of urban and rural Jackson, MS,
metropolitan tri-county (Hinds, Madison, and Rankin counties)
residents, volunteers, randomly selected individuals, and
secondary family members of enrolled participants.25 The
current analyses were restricted to 1148 participants who
underwent 24-hour ABPM following the baseline examination
in 2000–2004. Participants who did not meet the Interna-
tional Database of Ambulatory Blood Pressure in Relation to
Cardiovascular Outcome26 (IDACO) criteria for complete
ABPM (n=102; described below), did not have complete
echocardiography data on LVMI (n=27), or were missing clinic
BP values at the baseline visit (n=4) were excluded, leaving a
final sample size of 1015 participants.
The JHS was approved by the institutional review boards of
the University of Mississippi Medical Center, Jackson State
University, and Tougaloo College. The institutional review
boards at Columbia University and University of Alabama at
Birmingham approved the use of JHS data for the current
analysis. All participants provided written informed consent.
Data Collection and Clinical Covariates
A detailed description of the data collection, methodology,
and specimen collection and processing from examination 1
has been previously described and is available in Data S1.27,28
Data were collected during an in-home interview, clinic
examination, and a 24-hour ABPM period. During the in-home
interview, trained staff administered questionnaires to collect
self-reported information on sociodemographics, selected
health behaviors (eg, alcohol consumption, current smoking,
and physical activity), and prior diagnosed comorbid condi-
tions. During the clinic examination, trained technicians
measured height, weight, and BP, and collected blood and
urine samples. Antihypertensive medication use was defined
by self-report. After the clinic examination, participants were
given the opportunity to complete ABPM.
Clinic BP Measurement
Clinic BP measurements were taken using a Hawksley
random zero sphygmomanometer (Hawksley and Sons Ltd,
Lancing, United Kingdom) and an appropriately sized BP cuff.
Cuff size was determined by measuring the upper-arm
circumference. At each visit, participants rested for at least
5 minutes in a seated, upright position with their back and
arms supported, feet flat on the floor, and legs uncrossed
prior to having their BP measured. Trained staff conducted 2
BP measurements in the right arm. One minute elapsed
between the 2 measurements. The JHS Coordinating Center
conducted quality control by semiannual training and retrain-
ing of staff, monitoring digit preference for each technician,
and comparing mean BP measurements within and between
trained technicians. The 2 clinic-measured BP measurements
were averaged for analysis. As previously described, BP
measurements were calibrated using robust regression to an
oscillometric device (Omron HEM-907XL, Omron Healthcare
Inc., Lake Forest, IL).29 Prevalent clinic hypertension was
defined as a mean clinic SBP ≥140 mm Hg, mean clinic
diastolic BP (DBP) ≥90 mm Hg, or antihypertensive medica-
tion use.
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Ambulatory BP Monitoring
Participants were fitted with an ABPM device (Spacelabs
90207, Spacelabs, Redmond, WA) on their nondominant
arm following the baseline examination. Ambulatory BP
was recorded every 20 minutes. After 24 hours, the
device was removed and data were downloaded onto a
computer and processed with Medifacts International’s
Medicom software (Rockville, MD). IDACO criteria were
used to define whether the ABPM period was complete.
Specifically, participants were considered to have a
complete ABPM if they had ≥10 daytime (10 AM–8 PM)
and ≥5 nighttime (12 AM–6 AM) SBP and DBP measure-
ments.26 Mean daytime SBP and DBP and mean nighttime
SBP and DBP were calculated by averaging the readings
during the daytime and nighttime periods, respectively.
Mean 24-hour BP was defined by averaging all available
BP measurements from ABPM.
The nighttime to daytime SBP ratio was defined as mean
nighttime SBP divided by mean daytime SBP.6 Dipping was
categorized into 3 patterns based on the nighttime to
daytime SBP ratio: dipping pattern (≤0.90), nondipping
pattern (>0.90 to ≤1.00), and reverse dipping pattern
(>1.00). Because of the small sample size (n=38) of
participants with an extreme dipping pattern (≤0.80), these
participants were included in the dipping pattern category
(≤0.90).
Echocardiography
Certified sonographers performed 2-dimensional transtho-
racic echocardiography (Sonos-4500, Philips Medical Sys-
tems, Amsterdam, Netherlands) using standardized
protocols.27 Echocardiograms were reviewed for clinical
interpretation and analytical measurements by experienced
cardiologists on networked image workstations (Vericis;
Camtronics Medical Systems, Hartland, WI).27 Left ventricular
dimensions including left ventricular internal diameter in
diastole (mm), interventricular septal thickness in diastole
(IVSd, mm), and posterior wall thickness in diastole (PWTd,
mm), were assessed according to American Society of
Echocardiography (ASE) recommendations.30
Calculation of LVMI and LVH
Left ventricular mass, LVMI, and LVH were derived according to
ASE and European Society of Cardiovascular Imaging recom-
mendations.30 Left ventricular mass was calculated using the
ASE formula: 0.89(1.049((IVSD+LVEDD+PWTD)3(L-
VEDD)3))+0.6. LVMI was calculated as left ventricular mass/
body surface area.30 LVH was defined as increased LVMI
≥96 g/m2 in women and ≥116 g/m2 in men).30
Statistical Analyses
Participant characteristics were calculated for the overall
analytical sample and stratified into 3 dipping patterns
(dipping, nondipping, and reverse dipping). Values were
expressed as meanSD or percentages. Using ANOVA,
mean differencesstandard error (SE) in LVMI between
participants with dipping (referent), nondipping, and reverse
dipping patterns were determined. In addition to an
unadjusted model, 4 adjusted models were conducted
using ANCOVA. Model 1 included adjustment for age, sex,
and body mass index (BMI). Model 2 included the variables
in model 1 plus diabetes mellitus, education level achieved,
alcohol consumption, smoking status, physical activity,
reduced estimated glomerular filtration rate (<60 mL/min
per 1.73 m2), and antihypertensive medication use. Model
3 included adjustment for the variables in model 2 plus
mean clinic SBP. Model 4 included adjustment for the
variables in model 3 plus mean daytime SBP. The
prevalence of LVH between participants with dipping,
nondipping, and reverse dipping patterns was also calcu-
lated. Prevalence ratios (PRs) and 95% CIs for having LVH
were determined using Poisson regression models with
sandwich estimators before and after adjustment for
covariates as described for models 1 to 4 above, with
the dipping pattern serving as the reference group. In
secondary analyses, the differences in LVMI and preva-
lence of LVH between participants with dipping, nondip-
ping, and reverse dipping patterns were calculated by
substituting mean daytime SBP with mean 24-hour SBP in
model 4. In this model, the association of mean 24-hour
SBP with LVMI and LVH was also examined.
Mean differences in LVMI by quartiles of nighttime SBP
and quartiles of nighttime DBP, separately, were also
calculated using ANCOVA and Poisson regression. For
these analyses, the lowest quartile of nighttime SBP and
DBP were the referent groups. In analyses for nighttime
SBP, mean differences in LVMI were calculated before
and after adjustment for covariates in models 1 to 4. In
the analyses for nighttime DBP, model 3 included
adjustment for mean daytime DBP instead of mean
daytime SBP, and model 4 included adjustment for mean
clinic DBP instead of mean clinic SBP. PRs and 95% CIs
for having LVH associated with quartiles of nighttime SBP
and DBP were determined using Poisson regression
models with sandwich estimators before and after
adjustment for covariates as described for models 1 to
4 above.
Subgroup analyses were conducted by repeating the
analyses among participants taking and not taking
antihypertensive medication, separately. The tests for
interaction between antihypertensive medication use and
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dipping BP as well as nighttime SBP and nighttime DBP
on LVMI and LVH were calculated in models including the
full population, main effect terms, and multiplicative
interaction terms (eg, dipping pattern9antihypertensive
medication use). P<0.05 was considered to be statistically
significant. Analyses were conducted using SAS version
9.4 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Among the participants included in this analysis, the
meanSD age was 59.110.9 years, 67.9% were women,
63.0% had prevalent clinic hypertension, and 56.8% were
taking antihypertensive medication (Table 1). The prevalence
Table 1. Characteristics of Jackson Heart Study Participants Included in the Current Analysis, Overall, and Stratified by BP Dipping
Patterns
Overall
(N=1015)
Dipping
(n=341)
Nondipping
(n=489)
Reverse Dipping
(n=185)
P
Value*
Sociodemographic characteristics
Age, y 59.110.9 57.710.9 58.911.2 62.49.7 <0.001
Female sex, % 67.9 68.9 65.0 73.5 0.096
Education <high school, % 18.8 15.6 19.1 23.8 0.069
Clinical characteristics
Body mass index, kg/m2 31.16.5 30.06.0 31.56.7 32.16.4 <0.001
Diabetes mellitus, % 24.1 18.6 23.3 36.1 <0.001
Low-density lipoprotein cholesterol, mg/dL 125.836.0 128.536.5 124.833.9 123.640.0 0.251
High-density lipoprotein cholesterol, mg/dL 54.015.1 55.015.6 53.514.7 53.115.2 0.291
Estimated glomerular filtration rate <60 mL/min per 1.73 m2, % 10.9 7.7 10.3 18.1 0.001
Health behaviors
Alcohol use
Nondrinker, % 69.7 63.9 69.9 80.0 <0.001
Moderate drinker, % 28.1 32.6 28.2 19.5 0.006
Heavy drinker, % 2.2 3.5 1.8 0.5 0.064
Current smoking, % 10.0 11.7 8.4 10.8 0.260
Total physical activity score 8.32.6 8.52.5 8.32.6 7.92.6 0.063
High risk for sleep apnea, % 67.2 61.6 67.9 75.7 0.004
BP-related characteristics
Clinic BP
Mean systolic BP, mm Hg 127.715.9 126.315.6 127.815.7 130.316.9 0.028
Mean diastolic BP, mm Hg 74.58.5 74.38.8 74.58.3 74.98.7 0.766
Prevalent clinic hypertension†, % 63.0 58.4 60.3 78.8 <0.001
Antihypertensive medication use, % 56.8 52.1 53.2 74.9 <0.001
Ambulatory BP
Mean daytime systolic BP, mm Hg 129.413.5 130.913.3 128.613.4 128.914.1 0.039
Mean daytime diastolic BP, mm Hg 77.99.3 79.69.3 77.29.1 76.69.6 <0.001
Mean nighttime systolic BP, mm Hg 121.115.8 112.011.9 121.913.3 135.616.4 <0.001
Mean nighttime diastolic BP, mm Hg 68.49.8 63.68.6 69.08.7 75.69.7 <0.001
Mean 24-h systolic BP, mm Hg 126.313.7 123.512.6 126.113.4 132.115.0 <0.001
Mean 24-h diastolic BP, mm Hg 74.18.9 73.28.7 74.08.8 76.29.3 <0.001
Data are presented as meanSD or percentage. Dipping blood pressure (BP) (≤0.90), nondipping BP (>0.90 to ≤1.00), and reverse BP dipping (>1.00). Nighttime to daytime systolic BP
(SBP) ratio is defined as mean nighttime SBP divided by mean daytime SBP.
*Analysis of variance P value comparing differences between participants with dipping, nondipping, and reverse dipping patterns.
†Prevalent clinic hypertension is defined as a mean clinic SBP ≥140 mm Hg or mean clinic diastolic BP ≥90 mm Hg or self-report of current antihypertensive medication use.
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of dipping, nondipping, and reverse dipping patterns was
33.6%, 48.2%, and 18.2%, respectively. Among the 3 dipping
patterns, reverse dipping was associated with the oldest age,
highest body mass index and clinic SBP, and the highest
proportion of women, diabetes mellitus, reduced estimated
glomerular filtration rate, non-alcohol use, high risk for sleep
apnea, prevalent clinic hypertension, and antihypertensive
medication use.
Associations of BP Dipping Patterns With LVMI
and LVH
In an unadjusted model, compared with participants with a
dipping pattern, meanSE LVMI was 9.92.1 g/m2 higher
for participants with a reverse dipping pattern (P<0.001) and
1.61.6 g/m2 lower for participants with a nondipping
pattern (P=0.312, Table 2). In a fully adjusted model including
daytime SBP, compared with participants with a dipping
pattern, meanSE LVMI was 8.32.1 g/m2 higher for
participants with a reverse dipping pattern (P<0.001) and
1.01.6 g/m2 lower for participants with a nondipping
pattern (P=0.536). In a fully adjusted model controlling for
mean 24-hour SBP instead of mean daytime SBP (Table S1),
compared with participants with a dipping pattern, meanSE
LVMI was 5.12.1 g/m2 higher for participants with a
reverse dipping pattern (P=0.02) and 2.61.6 g/m2 lower
for participants with a nondipping pattern (P=0.113). In this
model, higher mean 24-hour SBP was associated with higher
LVMI (P<0.001, Table S2).
Among participants taking antihypertensive medication, the
prevalence of a dipping pattern, nondipping pattern, and
reverse dipping pattern was 30.8%, 45.4%, and 23.8%, respec-
tively. Among participants not taking antihypertensive medi-
cation, the prevalence of a dipping pattern, nondipping pattern,
and reverse dipping pattern was 37.1%, 52.3%, and 10.5%,
respectively. Among participants taking and not taking antihy-
pertensive medication, those with reverse dipping pattern had
11.02.8 and 2.13.4 g/m2 higher LVMI, respectively, com-
pared with their counterparts with a dipping pattern in a fully
adjusted model including mean daytime SBP (interaction
P=0.068, Table 3). In a fully adjusted model including mean
24-hour SBP instead of mean daytime SBP, compared with
participants with a dipping pattern, those with a reverse dipping
pattern had 7.72.8 g/m2 higher and 1.03.4 g/m2 lower
LVMI among those taking and not taking antihypertensive
medication, respectively (interaction P=0.096, Table S3).
The prevalence of LVH for participants with a dipping
pattern, nondipping pattern, and reverse dipping pattern was
11.1%, 10.6%, and 22.2%, respectively (Table 4). The PR for
having LVH for reverse dipping pattern versus dipping pattern
was 1.99 (95% CI, 1.33–2.98) in an unadjusted model. In a
fully adjusted model including mean daytime SBP, the PR for
having LVH for reverse dipping pattern versus dipping pattern
was 1.65 (95% CI, 1.05–2.58). The PR for having LVH was
1.21 (95% CI, 0.76–1.92) in a fully adjusted model when
adjusting for mean 24-hour SBP instead of mean daytime SBP
(Table S4). In this latter model, higher mean 24-hour SBP was
associated with an increased PR for having LVH (1.32 [95% CI,
1.15–1.51], Table S5).
In a fully adjusted model including mean daytime SBP, the
PRs for having LVH among participants with a reverse dipping
pattern versus a dipping pattern were 1.78 (95% CI, 1.07–
2.95) and 1.48 (95% CI, 0.52–4.16) among those taking and
not taking antihypertensive medication, respectively (interac-
tion P=0.904, Table 5). In a fully adjusted model including
mean 24-hour SBP instead of mean daytime SBP, the PRs for
having LVH among participants with a reverse dipping pattern
versus dipping pattern were 1.39 (95% CI, 0.83–2.33) and
Table 2. Differences in LVMI Between Participants With Nondipping and Reverse Dipping Versus Dipping BP Patterns
Dipping BP Patterns* P Value
Dipping (n=341) Nondipping (n=489) Reverse Dipping (n=185) Nondipping vs Dipping Reverse Dipping vs Dipping
LVMI, g/m2 78.220.8 76.621.2 88.129.7 0.312 <0.001
Differencestandard error
Unadjusted 0 (Ref) 1.61.6 9.92.1 0.312 <0.001
Model 1 0 (Ref) 2.51.6 8.12.1 0.116 <0.001
Model 2 0 (Ref) 1.81.6 7.02.1 0.282 <0.001
Model 3 0 (Ref) 1.91.6 6.92.1 0.245 0.001
Model 4 0 (Ref) 1.01.6 8.32.1 0.536 <0.001
Data are presented as meanSD or unadjusted/adjusted mean difference compared with referent (Ref) groupstandard error. Nighttime to daytime systolic blood pressure (SBP) ratio is
defined as mean nighttime SBP/mean daytime SBP. Model 1 includes adjustment for age, sex, and body mass index. Model 2 includes additional adjustment for diabetes mellitus,
education level, alcohol consumption, smoking status, physical activity, estimated glomerular filtration ratio <60 mL/min per 1.73 m2, and antihypertensive medication use. Model 3
includes additional adjustment for mean clinic SBP. Model 4 includes additional adjustment for mean daytime SBP. BP indicates blood pressure; LVMI, left ventricular mass index.
*Dipping pattern is based on the nighttime to daytime SBP ratio and defined by 3 patterns: dipping (≤0.90), nondipping (>0.90 to ≤1.00), and reverse dipping (>1.00).
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0.92 (95% CI, 0.33–2.59) among those taking and not taking
antihypertensive medication, respectively (interaction
P=0.504, Table S6).
The PRs for having LVH among participants with a
nondipping pattern versus their counterparts with a dipping
pattern were not statistically significant in an unadjusted
model (0.95 [95% CI, 0.64–1.42], Table 4) or a fully adjusted
model including either mean daytime SBP (0.96 [95% CI,
0.63–1.47], Table 4) or mean 24-hour SBP (0.82 [95% CI,
0.54–1.26], Table S4). In a fully adjusted model including
mean daytime SBP, the PRs for having LVH among partic-
ipants with a nondipping pattern versus dipping pattern were
0.96 (95% CI, 0.58–1.60) and 1.04 (95% CI, 0.47–2.31)
among those taking and not taking antihypertensive medica-
tion, respectively (interaction P=0.777, Table 5).
Association of Nighttime BP With LVMI and LVH
Higher quartiles of nighttime SBP and DBP were each
associated with higher LVMI in unadjusted and fully adjusted
models (Table 6). In an unadjusted model, the PRs for having
LVH associated with quartiles 2, 3, and 4 versus quartile 1 of
nighttime SBP were 1.21 (95% CI, 0.65–2.23), 2.13 (95% CI,
1.23–3.69), and 3.40 (95% CI, 2.04–5.69), respectively
(Table 7). The unadjusted PRs for LVH associated with
quartiles 2, 3, and 4 versus quartile 1 of nighttime DBP were
0.80 (95% CI, 0.48–1.34), 0.96 (95% CI, 0.59–1.57), and 1.79
(95% CI, 1.17–2.72), respectively. The associations of higher
quartiles of nighttime SBP and DBP with LVH were not
statistically significant in fully adjusted models.
The association between higher quartiles of nighttime SBP
and LVMI did not differ between participants taking versus not
taking antihypertensive medication (interaction P=0.853,
Table S7). In contrast, the association between higher quartiles
of nighttime DBP and LVMI was stronger among participants
taking versus not taking antihypertensivemedication (interaction
P<0.001, Table S8). Higher quartiles of nighttime SBP (Table S9)
and nighttime DBP (Table S10) were not associated with a
statistically significant increased prevalence of LVH among
participants taking and not taking antihypertensive medication.
Table 3. Differences in LVMI Among Participants With Dipping, Nondipping, and Reverse Dipping BP Patterns Stratified by
Antihypertensive Medication Use
Dipping BP Patterns*
P ValueAmong Participants Taking Antihypertensive Medication†
Dipping (n=173) Nondipping (n=255) Reverse Dipping (n=134) Nondipping vs Dipping Reverse Dipping vs Dipping
LVMI, g/m2 80.221.2 78.120.3 90.930.3 0.347 <0.001
Differencestandard error
Unadjusted 0 (Ref) 2.22.3 10.72.7 0.347 <0.001
Model 1 0 (Ref) 2.92.3 9.72.7 0.213 <0.001
Model 2 0 (Ref) 2.12.4 9.72.8 0.384 <0.001
Model 3 0 (Ref) 2.42.4 9.52.8 0.328 <0.001
Model 4 0 (Ref) 1.22.4 11.02.8 0.609 <0.001
Among Participants Not Taking Antihypertensive Medication P Value
Dipping (n=159) Nondipping (n=224) Reverse Dipping (n=45) Nondipping vs Dipping Reverse Dipping vs Dipping
LVMI, g/m2 75.820.2 74.121.3 77.020.5 0.439 0.737
Differencestandard error
Unadjusted 0 (Ref) 1.72.2 1.23.5 0.439 0.737
Model 1 0 (Ref) 2.42.1 0.73.4 0.264 0.850
Model 2 0 (Ref) 0.92.2 0.83.5 0.663 0.812
Model 3 0 (Ref) 1.02.2 0.63.5 0.653 0.855
Model 4 0 (Ref) 0.52.1 2.13.4 0.820 0.533
Data are presented as meanSD or unadjusted/adjusted mean difference compared with referent (Ref) groupstandard error. Model 1 includes adjustment for age, sex, and body mass
index. Model 2 includes additional adjustment for diabetes mellitus, education level, alcohol consumption, smoking status, physical activity, and estimated glomerular filtration ratio
<60 mL/min per 1.73 m2. Model 3 includes additional adjustment for mean clinic systolic blood pressure (SBP). Model 4 includes additional adjustment for mean daytime SBP. BP
indicates blood pressure; LVMI, left ventricular mass index.
*Dipping pattern is based on the nighttime to daytime SBP ratio and defined by 3 patterns: dipping (≤0.90), nondipping (>0.90 to ≤1.00), and reverse dipping (>1.00). Nighttime to daytime
SBP ratio is defined as mean nighttime SBP/mean daytime SBP.
†The overall test for interaction between antihypertensive medication use and dipping patterns on left ventricular mass index (LVMI) is P=0.086. The test for interaction between
antihypertensive medication use and nondipping pattern is P=0.707. The test for interaction between antihypertensive medication use and reverse dipping pattern is P=0.068.
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Discussion
In the current population-based study of blacks, participants
with a reverse dipping BP pattern had higher LVMI and a
higher prevalence of LVH when compared with their counter-
parts with a dipping BP pattern. These associations were
present after multivariable adjustment for demographics,
cardiovascular risk factors, antihypertensive medication use,
Table 4. Prevalence and Prevalence Ratios for LVH Associated With Dipping Patterns
Dipping Patterns*
Dipping (n=341) Nondipping (n=489) Reverse Dipping (n=185)
LVH, % 11.1 10.6 22.2
Prevalence ratio (95% CI)
Unadjusted 1 (Ref) 0.95 (0.64–1.42) 1.99 (1.33–2.98)
Model 1 1 (Ref) 0.91 (0.62–1.34) 1.66 (1.11–2.49)
Model 2 1 (Ref) 0.89 (0.58–1.37) 1.48 (0.95–2.32)
Model 3 1 (Ref) 0.88 (0.57–1.35) 1.47 (0.94–2.29)
Model 4 1 (Ref) 0.96 (0.63–1.47) 1.65 (1.05–2.58)
Left ventricular hypertrophy (LVH) is defined as left ventricular mass index ≥96 g/m2 in women and ≥116 g/m2 in men according to the American Society of Echocardiography
recommendations. Nighttime to daytime systolic blood pressure (SBP) ratio is defined as mean nighttime SBP/mean daytime SBP. Model 1 includes adjustment for age, sex, and body
mass index. Model 2 includes additional adjustment for diabetes mellitus, education level, alcohol consumption, smoking status, physical activity, estimated glomerular filtration ratio
<60 mL/min per 1.73 m2, and antihypertensive medication use. Model 3 includes additional adjustment for mean clinic SBP. Model 4 includes additional adjustment for mean daytime
SBP. Ref indicates referent.
*Dipping pattern is based on the nighttime to daytime SBP ratio and defined by three 3: dipping (≤0.90), nondipping (>0.90 to ≤1.00), and reverse dipping (>1.00).
Table 5. Prevalence Ratios for Having LVH Associated With Dipping Patterns Stratified by Antihypertensive Medication Use
Dipping Patterns*
Among Participants Taking Antihypertensive Medication†
Dipping (n=173) Nondipping (n=255) Reverse Dipping (n=134)
LVH, % 14.5 12.6 24.6
Prevalence ratio (95% CI)
Unadjusted 1 (Ref) 0.87 (0.53–1.41) 1.70 (1.07–2.72)
Model 1 1 (Ref) 0.87 (0.53–1.42) 1.64 (1.02–2.65)
Model 2 1 (Ref) 0.89 (0.53–1.50) 1.63 (0.98–2.70)
Model 3 1 (Ref) 0.88 (0.53–1.48) 1.61 (0.97–2.67)
Model 4 1 (Ref) 0.96 (0.58–1.60) 1.78 (1.07–2.95)
Among Participants Not Taking Antihypertensive Medication
Dipping (Ref) (n=159) Nondipping (n=224) Reverse Dipping (n=45)
LVH, % 7.6 6.7 11.1
Prevalence ratio (95% CI)
Unadjusted 1 (Ref) 0.89 (0.43–1.84) 1.47 (0.55–3.96)
Model 1 1 (Ref) 0.85 (0.42–1.72) 1.16 (0.43–3.15)
Model 2 1 (Ref) 0.98 (0.45–2.12) 1.25 (0.41–3.78)
Model 3 1 (Ref) 0.96 (0.44–2.10) 1.21 (0.40–3.61)
Model 4 1 (Ref) 1.04 (0.47–2.31) 1.48 (0.52–4.16)
Left ventricular hypertrophy (LVH) is defined as left ventricular mass index ≥96 g/m2 in women and ≥116 g/m2 in men according to the American Society of Echocardiography
recommendations. Model 1 includes adjustment for age, sex, and body mass index. Model 2 includes additional adjustment for diabetes mellitus, education level, alcohol consumption,
smoking status, physical activity, estimated glomerular filtration ratio <60 mL/min per 1.73 m2. Model 3 includes additional adjustment for mean clinic systolic blood pressure (SBP).
Model 4 includes additional adjustment for mean daytime SBP. Ref indicates referent.
*Dipping pattern is based on the nighttime to daytime SBP ratio and defined by 3 patterns: dipping (≤0.90), nondipping (>0.90 to ≤1.00), and reverse dipping (>1.00). Nighttime to daytime
SBP ratio is defined as mean nighttime SBP/mean daytime SBP.
†The overall test for interaction between antihypertensive medication use and dipping patterns on LVH is P=0.919. The test for interaction between antihypertensive medication use and
nondipping pattern is P=0.777. The test for interaction between antihypertensive medication use and reverse dipping pattern is P=0.904.
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clinic BP, and daytime BP. In contrast, participants with a
nondipping versus a dipping pattern did not have higher LVMI
or a higher prevalence of LVH. Further, higher nighttime BP
was associated with higher LVMI but not the prevalence of
LVH.
Although a reverse dipping pattern is associated with
increased mortality and cardiovascular events when com-
pared with a dipping pattern,5,8–12 it is unclear whether a
reverse dipping pattern also confers an increased risk for
subclinical cardiovascular target organ damage. Among 682
participants with hypertension, the majority of whom were not
taking antihypertensive medications in the Korean Ambulatory
Blood Pressure Study, there were no differences in LVMI
between participants with a reverse dipping or nondipping
pattern each versus a dipping pattern.18 In contrast, in a study
of 376 Serbian adults with untreated hypertension, reverse
dipping pattern and nondipping BP patterns were each
associated with higher LVMI when compared with a dipping
BP pattern.17 Additionally, 31% of participants with a reverse
dipping pattern and 17% of participants with a nondipping
pattern had LVH compared with only 9% of participants with a
dipping pattern. These studies17,18 were not population-
based, included mostly individuals who had untreated hyper-
tension, and did not include blacks. Several studies31–36 have
examined BP dipping in blacks or Caribbean blacks. These
studies were typically small,31,34 were not population-
based,31–34,36 did not examine reverse dipping31–34 or
LVMI,31–33 and did not consider antihypertensive medication
use.31–35 The results of our study are novel and extend the
findings of these prior studies by demonstrating in a large
population-based cohort of blacks that a reverse dipping
pattern is associated with higher LVMI and LVH, independent
of antihypertensive medication use.
Higher quartiles of nighttime SBP and nighttime DBP were
also associated with higher LVMI, highlighting the important
contribution of nighttime BP in cardiovascular disease risk.
Nighttime BP may be a stronger predictor of cardiovascular
events than daytime BP among individuals with treated
hypertension37,38 and among population-based cohorts.39 In
a population-based study of 1682 Italian participants,
nighttime SBP was associated with higher left ventricular
mass.40 Additionally, Yi et al18 demonstrated that the highest
Table 6. Differences in LVMI Associated With Quartiles (Qs) of Nighttime SBP (Upper Panel) and Nighttime DBP (Lower Panel)
Quartiles of Nighttime SBP
P TrendQ1 (n=253) Q2 (n=259) Q3 (n=258) Q4 (n=245)
Levels of nighttime SBP <109.5 mm Hg ≥109.5 and <119.4 mm Hg ≥119.4 and <130.8 mm Hg ≥130.8 mm Hg
LVMI, g/m2 73.018.8 74.717.9 80.023.5 89.728.0 <0.001
Differencestandard error
Unadjusted 0 (Ref) 1.72.0 7.02.0 16.72.0 <0.001
Model 1 0 (Ref) 0.42.0 4.92.0 13.02.1 <0.001
Model 2 0 (Ref) 0.32.0 4.42.0 10.42.2 <0.001
Model 3 0 (Ref) 0.42.0 4.32.1 10.22.3 <0.001
Model 4 0 (Ref) 1.42.1 2.02.3 6.32.9 0.026
Quartiles of Nighttime DBP
P TrendQ1 (n=255) Q2 (n=253) Q3 (n=256) Q4 (n=251)
Levels of nighttime DBP <61.7 mm Hg ≥61.7 and <67.5 mm Hg ≥67.5 and <74.4 mm Hg ≥74.4 mm Hg
LVMI, g/m2 76.422.9 74.919.0 78.720.0 87.028.2 <0.001
Differencestandard error
Unadjusted 0 (Ref) 1.52.0 2.32.0 10.62.0 <0.001
Model 1 0 (Ref) 1.22.0 2.32.0 9.62.1 <0.001
Model 2 0 (Ref) 2.12.0 1.32.1 7.02.1 <0.001
Model 3 0 (Ref) 1.82.1 1.82.1 7.82.2 <0.001
Model 4 0 (Ref) 2.42.1 0.42.3 5.32.7 0.013
Data are presented as meanSD or unadjusted/adjusted mean difference compared with referent (Ref) groupstandard error. Upper panel: Model 1 includes adjustment for age, sex, and
body mass index. Model 2 includes additional adjustment for diabetes mellitus, education level, alcohol consumption, smoking status, physical activity, estimated glomerular filtration ratio
<60 mL/min per 1.73 m2, and antihypertensive mediation use. Model 3 includes model 2 plus additional adjustment for mean clinic systolic blood pressure (SBP). Model 4 includes bodel
3 plus additional adjustment for mean daytime SBP. Lower panel: Model 1 includes adjustment for age, sex, and body mass index. Model 2 includes additional adjustment for diabetes
mellitus, education level, alcohol consumption, smoking status, physical activity, estimated glomerular filtration ratio <60 mL/min per 1.73 m2, and antihypertensive mediation use. Model
3 includes model 3 plus additional adjustment for mean clinic diastolic blood pressure (DBP). Model 4 includes model 2 plus additional adjustment for mean daytime DBP.
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versus lowest quartile of nighttime SBP was associated with
higher LVMI among individuals with untreated and treated
hypertension. The results from the current study extend both
these findings by demonstrating that higher nighttime BP
was associated with increased LVMI, independent of clinic
BP and daytime BP among a population-based sample of
blacks.
In the current study, the associations of reverse dipping
pattern with LVMI and LVH were smaller when adjusting for
mean 24-hour SBP instead of mean daytime SBP. These
results indicate that the associations of reverse dipping
pattern with cardiovascular target organ damage may be
explained by higher mean 24-hour SBP levels, and that
reverse dipping may represent an ABPM phenotype for which
daytime BP but not nighttime BP is controlled. Therefore,
among blacks, BP control over the daytime and nighttime
periods may be associated with a larger reduction in
cardiovascular disease risk compared with BP control only
during the daytime period. Some studies41–43 have previously
demonstrated that nighttime dosing of antihypertensive
medications may improve nighttime and 24-hour BP control
and restores dipping BP among adults with nondipping BP.
Given the results of the current study, future studies should
examine whether nighttime dosing of antihypertensive med-
ications lowers the risk of cardiovascular target organ damage
or cardiovascular disease events among blacks with a reverse
dipping pattern.
In the current study, 18.2% of participants had a reverse
dipping pattern; 23.8% and 10.5% for those taking and not
taking antihypertensive medication, respectively. The preva-
lence of a reverse dipping pattern among participants taking
antihypertensive medication was high, which is consistent
with the findings of prior studies for which the prevalence
ranged from 15.6% to 26.7% among individuals with treated
hypertension.9,18,37,44–46 Although the timing of antihyperten-
sive medication was not recorded in the JHS, it is likely that
most participants took their medications during the daytime
period. Therefore, the higher prevalence of reverse dipping
Table 7. Prevalence and Prevalence Ratios for LVH Associated With Quartiles (Qs) of Nighttime SBP (Upper Panel) and Nighttime
DBP (Lower Panel)
Quartiles of Nighttime SBP
Q1 (n=253) Q2 (n=259) Q3 (n=258) Q4 (n=245)
Levels of nighttime SBP <109.5 mm Hg ≥109.5 and <119.4 mm Hg ≥119.4 and <130.8 mm Hg ≥130.8 mm Hg
LVH, % 6.7 8.1 14.3 22.9
Prevalence ratio (95% CI)
Unadjusted 1 (Ref) 1.21 (0.65–2.23) 2.13 (1.23–3.69) 3.40 (2.04–5.69)
Model 1 1 (Ref) 1.12 (0.61–2.06) 1.87 (1.07–3.28) 2.76 (1.59–4.80)
Model 2 1 (Ref) 1.03 (0.52–2.04) 1.85 (1.03–3.34) 2.40 (1.31–4.39)
Model 3 1 (Ref) 1.03 (0.52–2.05) 1.85 (1.29–4.47) 2.40 (1.29–4.47)
Model 4 1 (Ref) 0.93 (0.46–1.86) 1.43 (0.75–2.75) 1.51 (0.69–3.29)
Quartiles of Nighttime DBP
Q1 (n=255) Q2 (n=253) Q3 (n=256) Q4 (n=251)
Levels of nighttime DBP <61.7 mm Hg ≥61.7 and <67.5 mm Hg ≥67.5 and <74.4 mm Hg ≥74.4 mm Hg
LVH, % 11.4 9.1 10.9 20.3
Prevalence ratio (95% CI)
Unadjusted 1 (Ref) 0.80 (0.48–1.34) 0.96 (0.59–1.57) 1.79 (1.17–2.72)
Model 1 1 (Ref) 0.89 (0.53–1.48) 1.21 (0.74–1.97) 2.24 (1.45–3.46)
Model 2 1 (Ref) 0.77 (0.44–1.35) 1.04 (0.61–1.79) 1.86 (1.16–2.99)
Model 3 1 (Ref) 0.80 (0.45–1.41) 1.11 (0.64–1.92) 2.02 (1.24–3.29)
Model 4 1 (Ref) 0.74 (0.42–1.31) 0.94 (0.53–1.67) 1.49 (0.79–2.78)
Left ventricular hypertrophy (LVH) is defined as left ventricular mass index ≥96 g/m2 in women and ≥116 g/m2 in men according to the American Society of Echocardiography
recommendations. Upper panel: Model 1 includes adjustment for age, sex, and body mass index. Model 2 includes additional adjustment for diabetes mellitus, education level, alcohol
consumption, smoking status, physical activity, estimated glomerular filtration ratio <60 mL/min per 1.73 m2, and antihypertensive mediation use. Model 3 includes model 2 plus
additional adjustment for mean clinic SBP. Model 4 includes model 3 plus additional adjustment for mean daytime systolic blood pressure (SBP). Lower panel: Model 1 includes adjustment
for age, sex, and body mass index. Model 2 includes additional adjustment for diabetes mellitus, education level, alcohol consumption, smoking status, physical activity, estimated
glomerular filtration ratio <60 mL/min per 1.73 m2, and antihypertensive mediation use. Model 3 includes model 3 plus additional adjustment for mean clinic diastolic blood pressure
(DBP). Model 4 includes model 2 plus additional adjustment for mean daytime DBP. Ref indicates referent.
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pattern among those taking versus not taking antihyperten-
sive medication may be partially explained by the daytime
dosing of antihypertensive medication, leading to a reduction
in daytime relative to nighttime BP. In the current study, the
prevalence of having a high risk of sleep apnea was highest
among participants with a reverse dipping pattern. Therefore,
another explanation for the high prevalence of reverse dipping
pattern is sleep apnea, which is common among individuals
with treated hypertension and is associated with higher
nighttime BP and a high prevalence of nondipping BP
pattern.47–50
Finally, in the current study, the associations of reverse
dipping with LVMI and LVH appeared to be evident only
among participants taking antihypertensive medication.
Although this finding suggests that reverse dipping may be
more benign among those not taking antihypertensive
medication, there was no evidence of an interaction between
antihypertensive medication and dipping patterns on LVMI
and LVH, indicating that the associations of reverse dipping
with LVMI and LVH were not modified by antihypertensive
medication use.
Study Strengths and Limitations
There are several strengths of the current study. We used data
from a large and well-characterized population-based cohort
of blacks. The JHS is one of the largest studies of ABPM
conducted among blacks. Further, high-quality echocardiog-
raphy was conducted among JHS participants using standard-
ized procedures. There are also several possible limitations.
Participants in JHS underwent ABPM during only one 24-hour
period, and the short-term reproducibility of dipping patterns
may be limited.51 The study had only a few participants (n=38)
with an extreme dipping pattern. Sleep diaries and informa-
tion regarding reasons for nighttime awakening, which may
impact nighttime BP, were not collected. Lastly, the current
analysis was cross-sectional, and we cannot determine the
direction of the association between dipping patterns and
LVMI and LVH.
Conclusions
Approximately 1 in 5 blacks in the current study had a reverse
dipping pattern. Participants with a reverse dipping pattern
had higher LVMI and a higher prevalence of LVH compared
with participants with a dipping pattern, Further, higher
nighttime SBP and DBP values were associated with higher
levels of LVMI. The data from the current study suggest that
the identification of a reverse dipping pattern on ABPM may
identify blacks at increased risk for cardiovascular target
organ damage.
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SUPPLEMENTAL MATERIAL 
 
Data S1. 
 
Supplemental Methods 
 
Data Collection & Clinical Covariates 
 
During clinic examination, trained African American interviewers administered 
standardized questionnaires to assess selected demographic and behavior 
characteristics: age, sex, education, marital status, socioeconomic status, alcohol 
consumption, current smoking, and physical activity.1 Education was measured as the 
highest level of schooling completed and classified into two categories within this study 
as “less than high school” or “greater than high school”. Physical activity over the past 
12 months was assessed using the JHS Physical Activity Cohort (JPAC) survey, a 30-
item validated questionnaire.2, 3 The JPAC has four index scores that correspond to four 
physical activity domains (active living, work, sport, and home/life). The total physical 
activity score was calculated as the sum of the four index scores, with work scores set 
to 0 for participants who reported no paid or volunteer work during the past year. Higher 
scores represent more daily physical activity. Current smoking was defined by 
affirmative responses to the questions “Have you smoked more than 400 cigarettes in 
your lifetime?” and “Do you now smoke cigarettes?” Daily alcohol consumption was 
assessed from a validated food frequency questionnaire4 and in our study defined as 
“none”: 0 drinks/week, “moderate” consumption: 1-14 and 1-7 alcoholic drinks/week for 
men and women respectively, and “heavy” consumption: >14 and >7 alcoholic 
drinks/week for men and women respectively.5 Risk of obstructive sleep apnea was 
assessed using the STOP-BANG questionnaire.6, 7 The STOP-BANG questionnaire has 
8 questions that assess the following attributes: snoring loudly, breathing cessation 
during sleep, tiredness during the daytime, hypertension status, body mass index >35 
kg/m2, being aged >50 years, and having a neck circumference > 40 cm and being 
male. Individuals with ≥3 attributes described above were categorized as high risk for 
obstructive sleep apnea. 
 Participants were asked to bring any medications taken within 2 weeks prior to 
the baseline examination to the clinic visit and were transcribed verbatim.  Medication 
coding was performed by a pharmacist using the Medispan dictionary and classified into 
categories according to the Therapeutic Classification System. Antihypertensive 
medication use was defined by self-report. Participants were asked to avoid caffeine, 
eating, heavy physical activity, smoking, and alcohol intake for 12 hours prior to the 
clinic examination. During the clinic examination, weight and height were measured for 
each participant. Body mass index was calculated as the weight in kilograms divided by 
height in meters squared (kg/m2). Fasting blood samples were collected according to 
standardized procedures8 and processed at two central laboratories (University of 
Mississippi Medical Center and the University of Minnesota).8 Total and high-density 
lipoprotein (HDL) cholesterol was quantified by an oxidase method and low-density 
lipoprotein (LDL) cholesterol was calculated using the Freidewald equation.8 Estimated 
glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation.9 Reduced eGFR was defined as <60 
ml/min/1.73 m2. Diabetes was defined as a fasting (≥8 hours) serum glucose ≥126 
mg/dL or hemoglobin A1c ≥6.5% or use of insulin or oral hypoglycemic medications 
within 2 weeks prior to the clinic examination. 
 
Table S1. Differences in left ventricular mass index* between participants with non-dipping and reverse dipping versus 
dipping blood pressure patterns. 
 Dipping BP patterns† P-Value 
 
Dipping  
(N=341) 
Non-dipping 
(N=489) 
Reverse dipping 
(N=185) 
Non-dipping 
versus Dipping 
Reverse dipping 
versus Dipping 
LVMI (g/m2) 78.2 ± 20.8 76.6 ± 21.2 88.1 ± 29.7 0.312 <0.001 
 Difference ± standard error   
 0 (ref) -2.6 ± 1.6 5.1 ± 2.1 0.113 0.02 
Data presented as mean ± standard deviation or unadjusted/adjusted mean difference compared to referent group ± standard error.  
BP=blood pressure 
LVMI=left ventricular mass index 
Ref=referent 
SBP=systolic blood pressure 
*Adjusted for age, sex, and body mass index, diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2, antihypertensive medication use, mean clinic SBP, and mean 24-hour SBP. 
†Dipping pattern is based on the nighttime-to-daytime SBP ratio and defined by three patterns: dipping (≤0.90), non-dipping (>0.90 to 
≤1.00) and reverse dipping (>1.00). Nighttime-to-daytime SBP ratio is defined as mean nighttime SBP/mean daytime SBP.  
 
 
Table S2. Association between mean 24-hour SBP and left ventricular mass index. 
 B coefficient ± standard error* P-value 
Mean 24-hour SBP, per 10 mmHg increase 3.1 ± 0.6 <0.001 
B= beta 
SBP=systolic blood pressure 
*Adjusted for age, sex, and body mass index, diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2, antihypertensive medication use, mean clinic SBP, and dipping BP patterns. 
Dipping pattern is based on the nighttime-to-daytime SBP ratio and defined by three patterns: dipping (≤0.90), non-dipping (>0.90 to 
≤1.00) and reverse dipping (>1.00). Nighttime-to-daytime SBP ratio is defined as mean nighttime SBP/mean daytime SBP.   
Table S3. Differences in left ventricular mass index* among participants with dipping, non-dipping, and reverse dipping 
blood pressure patterns stratified by antihypertensive medication use. 
  Dipping BP patterns†  
 Among participants taking antihypertensive medication‡ P-value 
 Dipping 
(N=173) 
Non-dipping 
(N=255) 
Reverse dipping 
(N=134) 
Non-dipping 
versus Dipping 
Reverse dipping  
versus Dipping  
LVMI (g/m2) 80.2 ± 21.2 78.1 ± 20.3 90.9 ± 30.3 0.347 <0.001 
 Difference ± standard error   
 0 (ref) -2.9 ± 2.4 7.7 ± 2.8 0.224 0.007 
 Among participants not taking antihypertensive medication   
 Dipping 
(N=159) 
Non-dipping 
(N=224) 
Reverse dipping 
(N=45) 
Non-dipping 
versus Dipping 
Reverse dipping  
versus Dipping  
LVMI (g/m2) 75.8 ± 20.2 74.1 ± 21.3 77.0 ± 20.5 0.439 0.737 
 Difference ± standard error   
 0 (ref) -2.0 ± 2.1 -1.0 ± 3.4 0.361 0.774 
Data presented as mean ± standard deviation or unadjusted/adjusted mean difference compared to referent group ± standard error.  
LVMI=left ventricular mass index 
Ref=referent 
SBP=systolic blood pressure 
*Adjusted for age, sex, and body mass index, diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2, antihypertensive medication use, mean clinic SBP, and mean 24-hour SBP. 
†Dipping pattern is based on the nighttime-to-daytime SBP ratio and defined by three patterns: dipping (≤0.90), non-dipping (>0.90 to 
≤1.00) and reverse dipping (>1.00). Nighttime-to-daytime SBP ratio is defined as mean nighttime SBP/mean daytime SBP.  
‡The overall test for interaction between antihypertensive medication use and dipping patterns on LVMI is p=0.100. The test for 
interaction between antihypertensive medication use and non-dipping pattern is p=0.596. The test for interaction between 
antihypertensive medication use and reverse dipping pattern is p= 0.096. 
Table S4. Prevalence and prevalence ratios* for left ventricular hypertrophy associated with dipping patterns. 
 Dipping patterns† 
 Dipping  
(N=341) 
Non-dipping 
(N=489) 
Reverse dipping 
(N=185) 
LVH, %  11.1% 10.6% 22.2% 
 Prevalence ratio (95% confidence interval) 
 1 (ref) 0.82 (0.54 – 1.26) 1.21 (0.76 – 1.92) 
Left ventricular hypertrophy defined as LVMI ≥ 96 g/m2 in females and LVMI ≥ 116 g/m2 in males according to the American Society 
of Echocardiography recommendations.  
BP=blood pressure 
LVH=left ventricular hypertrophy 
LVMI=left ventricular mass index 
Ref=referent 
SBP=systolic blood pressure 
*Adjusted for age, sex, and body mass index, diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2, antihypertensive medication use, mean clinic SBP, and mean 24-hour SBP. 
†Dipping pattern is based on the nighttime-to-daytime SBP ratio and defined by three patterns: dipping (≤0.90), non-dipping (>0.90 to 
≤1.00) and reverse dipping (>1.00). Nighttime-to-daytime SBP ratio is defined as mean nighttime SBP/mean daytime SBP.  
 
 
 
 
 
 
 
Table S5. Association between mean 24-hour SBP and left ventricular hypertrophy.  
 Prevalence ratio (95% confidence interval)* P-value 
Mean 24-hour SBP, per 10 mmHg 
increase 
1.32 (1.15 – 1.51) <0.001 
SBP=systolic blood pressure 
*Adjusted for age, sex, and body mass index, diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2, antihypertensive medication use, mean clinic SBP, and dipping BP patterns.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S6. Prevalence ratios* for having left ventricular hypertrophy associated with dipping patterns stratified by 
antihypertensive medication use. 
 Dipping patterns† 
 Among participants taking antihypertensive medication‡ 
 Dipping 
(N=173) 
Non-dipping 
(N=255) 
Reverse dipping 
(N=134) 
LVH, %  14.5% 12.6% 24.6% 
 Prevalence ratio (95% confidence interval) 
 1 (ref) 0.84 (0.51 – 1.40) 1.39 (0.83 – 2.33) 
 Among participants not taking antihypertensive medication  
 Dipping (ref) 
(N=159) 
Non-dipping 
(N=224) 
Reverse dipping 
(N=45) 
LVH, %  7.6% 6.7% 11.1% 
 Prevalence ratio (95% confidence interval) 
 1 (ref) 0.82 (0.36 – 1.88) 0.92 (0.33 – 2.59) 
Left ventricular hypertrophy defined as LVMI ≥ 96 g/m2 in females and LVMI ≥ 116 g/m2 in males according to the 
American Society of Echocardiography recommendations.  
LVH=left ventricular hypertrophy 
LVMI=left ventricular mass index 
Ref=referent 
SBP=systolic blood pressure 
*Adjusted for age, sex, and body mass index, diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2, antihypertensive medication use, mean clinic SBP, and mean 24-hour SBP. 
†Dipping pattern is based on the nighttime-to-daytime SBP ratio and defined by three patterns: dipping (≤0.90), non-dipping (>0.90 to 
≤1.00) and reverse dipping (>1.00). Nighttime-to-daytime SBP ratio is defined as mean nighttime SBP/mean daytime SBP.  
‡The overall test for interaction between antihypertensive medication use and dipping patterns on LVH is p=0.908. The test for 
interaction between antihypertensive medication use and non-dipping pattern is p=0.333. The test for interaction between 
antihypertensive medication use and reverse dipping pattern is p=0.504. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S7. Differences in left ventricular mass index associated with quartiles of nighttime systolic blood pressure stratified 
by antihypertensive medication use. 
 Quartiles of Nighttime SBP  
 Among participants taking antihypertensive medication*  
 
Q1  
(n=107) 
Q2 
(N=140) 
Q3 
(N=143) 
Q4 
(N=172) 
P-trend 
Levels of  
Nighttime SBP 
< 109.5 
mmHg 
≥109.5 and < 119.4 mmHg ≥119.4 and < 130.8 
mmHg 
≥ 130.8 
mmHg 
 
LVMI (g/m2) 76.8 ± 21.8 76.3 ± 19.1 81.3 ± 22.4 89.8 ± 27.4 <0.001 
 Difference ± standard error  
Unadjusted 0 (ref) -0.6 ± 3.0 4.5 ± 3.0 13.0 ± 2.9 <0.001 
Model 1 0 (ref) -1.2 ± 3.0 3.4 ± 3.0 10.9 ± 2.9 <0.001 
Model 2 0 (ref) -1.3 ± 3.1 5.2 ± 3.1 10.8 ± 3.1 <0.001 
Model 3 0 (ref) -1.3 ± 3.2 5.2 ± 3.2 10.9 ± 3.3 <0.001 
Model 4 0 (ref) -1.6 ± 3.2 4.2 ± 3.4 9.1 ± 3.9 0.020 
  Among participants not taking antihypertensive medication   
 
Q1  
(n=142) 
Q2 
(N=113) 
Q3 
(N=107) 
Q4 
(N=66) 
P-trend 
Levels of  
Nighttime SBP 
< 109.5 
mmHg 
≥109.5 and < 119.4 mmHg ≥119.4 and < 130.8 
mmHg 
≥ 130.8 
mmHg 
 
LVMI (g/m2) 70.2 ± 15.9 73.2 ± 16.4 76.6 ± 23.8 86.2 ± 26.8 <0.001 
 Difference ± standard error  
Data presented as mean ± standard deviation or unadjusted/adjusted mean difference compared to referent group ± standard error. 
LVMI=left ventricular mass index 
Q=quartile 
Ref=referent 
SBP=systolic blood pressure 
Model 1 includes adjustment for age, sex, and body mass index.  
Model 2 includes additional adjustment for diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2. 
Model 3 includes additional adjustment for mean clinic SBP. 
Model 4 includes additional adjustment for mean daytime SBP.  
*The overall test for interaction between antihypertensive medication use and quartiles of nighttime SBP on LVMI is p=0.853. The 
test for interaction between antihypertensive medication use and quartiles 2, 3, and 4 of nighttime SBP, separately are p=0.558, 
p=0.778, and p=0.921, respectively.  
 
 
 
 
 
 
 
 
Unadjusted 0 (ref) 3.1 ± 2.5 6.4 ± 2.6 16.0 ± 3.0 <0.001 
Model 1 0 (ref) 1.9 ± 2.5 4.3 ± 2.6 12.5 ± 3.1 0.003 
Model 2 0 (ref) 0.9 ± 2.6 3.4 ± 2.7 9.8 ± 3.3 0.022 
Model 3 0 (ref) 0.8 ± 2.6 3.1 ± 2.8 9.4 ± 3.6 0.056 
Model 4 0 (ref) -1.9 ± 2.7 -1.3 ± 3.2 1.1 ± 4.6 0.767 
Table S8. Differences in left ventricular mass index associated with quartiles of nighttime diastolic blood pressure stratified 
by antihypertensive medication use. 
 Quartiles of Nighttime DBP  
 Among participants taking antihypertensive medication*  
 
Q1  
(n=141) 
Q2 
(N=132) 
Q3 
(N=137) 
Q4 
(N=152) 
P-trend 
Levels of  
Nighttime DBP 
< 61.7 mmHg ≥61.7 and < 67.5 mmHg ≥67.5 and < 74.4 mmHg ≥ 74.4 mmHg  
LVMI (g/m2) 80.1 ± 24.1 76.9 ± 18.1 78.3 ± 19.7 90.8 ± 28.7 <0.001 
 Difference ± standard error  
Unadjusted 0 (ref) -3.3 ± 2.8 -1.9 ± 2.8 10.7 ± 2.7 <0.001 
Model 1 0 (ref) -2.4 ± 2.8 -0.8 ± 2.8 11.2 ± 2.9 <0.001 
Model 2 0 (ref) -2.5 ± 3.0 -1.6 ± 3.0 10.3 ± 3.0 <0.001 
Model 3 0 (ref) -2.0 ± 3.0 -0.8 ± 3.0 11.6 ± 3.2 <0.001 
Model 4 0 (ref) -2.1 ± 3.0 -1.1 ± 3.2 11.0 ± 3.7 <0.001 
  Among participants not taking antihypertensive medication   
 
Q1  
(n=109) 
Q2 
(N=113) 
Q3 
(N=116) 
Q4 
(N=90) 
P-trend 
Levels of  
Nighttime DBP 
< 61.7 mmHg ≥61.7 and < 67.5 mmHg ≥67.5 and <74.4 mmHg ≥ 74.4 mmHg  
LVMI (g/m2) 71.8 ± 20.9 72.4 ± 19.6 78.7 ± 20.1 77.6 ± 22.3 0.023 
 Difference ± standard error  
Data presented as mean ± standard deviation or unadjusted/adjusted mean difference compared to referent group ± standard error. 
DBP=diastolic blood pressure 
LVMI=left ventricular mass index 
Q=quartile 
Ref=referent 
Model 1 includes adjustment for age, sex, and body mass index.  
Model 2 includes additional adjustment for diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2. 
Model 3 includes additional adjustment for mean clinic DBP. 
Model 4 includes additional adjustment for mean daytime DBP. 
*The overall test for interaction between antihypertensive medication use and quartiles of nighttime DBP on LVMI is p<0.001. The 
test for interaction between antihypertensive medication use and quartiles 2, 3, and 4 of nighttime DBP, separately are p=0.989, 
p=0.158, and p=0.054, respectively.  
 
 
 
 
 
 
 
 
Unadjusted 0 (ref) 0.6 ± 2.8 6.9 ± 2.8 5.8 ± 2.9 0.023 
Model 1 0 (ref) -0.4 ± 2.7 5.1 ± 2.7 3.7 ± 2.9 0.113 
Model 2 0 (ref) -1.5 ± 2.8 5.0 ± 2.8 2.7 ± 3.0 0.086 
Model 3 0 (ref) -1.5 ± 2.8 5.1 ± 2.9 2.9 ± 3.2 0.086 
Model 4 0 (ref) -2.8 ± 2.8 2.2 ± 3.1 -2.3 ± 4.0 0.243 
Table S9. Prevalence and prevalence ratios for left ventricular hypertrophy associated with quartiles of nighttime systolic 
blood pressure stratified by antihypertensive medication use.  
Quartiles of Nighttime SBP 
Among participants taking antihypertensive medication* 
 
Q1  
(n=107) 
Q2 
(N=140) 
Q3 
(N=143) 
Q4 
(N=172) 
Levels of  
Nighttime SBP 
< 109.5 mmHg ≥109.5 and < 119.4 mmHg ≥119.4 and < 130.8 mmHg ≥ 130.8 mmHg 
LVH, % 12.2% 10.7% 16.8% 22.1% 
Prevalence ratio (95% confidence interval) 
Unadjusted 1 (ref) 0.88 (0.44 – 1.77) 1.38 (0.74 – 2.59) 1.82 (1.02 – 3.25) 
Model 1 1 (ref) 0.90 (0.45 – 1.80) 1.38 (0.73 – 2.61) 1.84 (1.00 – 3.39) 
Model 2 1 (ref) 0.89 (0.40 – 2.02) 1.74 (0.88 – 3.44)  2.05 (1.05 – 4.02) 
Model 3 1 (ref) 0.91 (0.40 – 2.05) 1.78 (0.89 – 3.55) 2.14 (1.07 – 4.29) 
Model 4 1 (ref) 0.87 (0.38 – 1.97) 1.52 (0.73 – 3.20) 1.62 (0.69 – 3.78) 
Among participants not taking antihypertensive medication 
 
Q1  
(n=142) 
Q2 
(N=113) 
Q3 
(N=107) 
Q4 
(N=66) 
Levels of  
Nighttime SBP 
< 109.5 mmHg ≥109.5 and < 119.4 mmHg ≥119.4 and < 130.8 mmHg ≥ 130.8 mmHg 
LVH, % 2.8% 5.3% 8.4% 19.7% 
LVH=left ventricular hypertrophy 
Q=quartile 
Ref=referent 
SBP=systolic blood pressure 
Model 1 includes adjustment for age, sex, and body mass index.  
Model 2 includes additional adjustment for diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2. 
Model 3 includes additional adjustment for mean clinic SBP. 
Model 4 includes additional adjustment for mean daytime SBP.  
*The overall test for interaction between antihypertensive medication use and quartiles of nighttime SBP on LVH is p=0.530. The test 
for interaction between antihypertensive medication use and quartiles 2, 3, and 4 of nighttime SBP, separately are p=0.550, p=0.644, 
and p=0.192, respectively.  
 
 
 
 
 
 
 
 
Prevalence ratio (95% confidence interval) 
Unadjusted 1 (ref) 1.88 (0.55 – 6.52) 2.99 (0.94 – 9.44) 7.00 (2.37 – 20.63) 
Model 1 1 (ref) 1.66 (0.47 – 5.83) 2.35 (0.72 – 7.66) 4.74 (1.42 – 15.83) 
Model 2 1 (ref) 1.27 (0.33 – 4.85) 1.79 (0.55 – 5.83) 3.19 (0.94 – 10.87) 
Model 3 1 (ref) 1.26 (0.33 – 4.82) 1.78 (0.54 – 5.81) 3.13 (0.91 – 10.79) 
Model 4 1 (ref) 0.93 (0.22 – 3.89) 1.06 (0.28 – 3.96) 1.18 (0.20 – 6.91) 
Table S10. Prevalence and prevalence ratios for left ventricular hypertrophy associated with quartiles of nighttime 
diastolic blood pressure stratified by antihypertensive medication use.  
Quartiles of Nighttime DBP 
Among participants taking antihypertensive medication* 
 
Q1  
(n=141) 
Q2 
(N=132) 
Q3 
(N=137) 
Q4 
(N=152) 
Levels of  
Nighttime DBP 
< 61.7 mmHg ≥61.7 and < 67.5 mmHg ≥67.5 and < 74.4 mmHg ≥ 74.4 mmHg 
LVH, % 17.0% 11.4% 11.7% 23.0% 
Prevalence ratio (95% confidence interval) 
Unadjusted 1 (ref) 0.67 (0.37 – 1.22) 0.69 (0.38 – 1.23) 1.35 (0.85 – 2.16) 
Model 1 1 (ref) 0.72 (0.39 – 1.31) 0.82 (0.45 – 1.50) 1.74 (1.06 – 2.84) 
Model 2 1 (ref) 0.66 (0.34 – 1.28) 0.70 (0.36 – 1.35) 1.62 (0.95 – 2.75) 
Model 3 1 (ref) 0.68 (0.35 – 1.33) 0.74 (0.38 – 1.43) 1.74 (1.01 – 2.99) 
Model 4 1 (ref) 0.67 (0.34 – 1.30) 0.70 (0.35 – 1.41) 1.59 (0.79 – 3.19) 
Among participants not taking antihypertensive medication 
 
Q1  
(n=109) 
Q2 
(N=113) 
Q3 
(N=116) 
Q4 
(N=90) 
Levels of  
Nighttime DBP 
< 61.7 mmHg ≥61.7 and < 67.5 mmHg ≥67.5 and < 74.4 mmHg ≥ 74.4 mmHg 
LVH, % 4.6% 5.3% 9.5% 11.1% 
DBP=diastolic blood pressure 
LVH=left ventricular hypertrophy 
Q=quartile 
Ref=referent 
Model 1 includes adjustment for age, sex, and body mass index.  
Model 2 includes additional adjustment for diabetes, education level, alcohol consumption, smoking status, physical activity, 
estimated glomerular filtration ratio < 60 ml/min/1.73m2 
Model 3 includes additional adjustment for mean clinic DBP. 
Model 4 includes additional adjustment for mean daytime DBP. 
*The overall test for interaction between antihypertensive medication use and quartiles of nighttime DBP on LVH is p=0.434. The test 
for interaction between antihypertensive medication use and quartiles 2, 3, and 4 of nighttime DBP, separately are p=0.445, p=0.115, 
and p=0.490, respectively.  
 
 
Prevalence ratio (95% confidence interval) 
Unadjusted 1 (ref) 1.16 (0.36 – 3.68) 2.07 (0.74 – 5.76) 2.42 (0.86 – 6.83) 
Model 1 1 (ref) 1.26 (0.40 – 3.98) 2.66 (0.96 – 7.37) 2.99 (1.01 – 8.86) 
Model 2 1 (ref) 1.07 (0.32 – 3.66) 2.88 (0.92 – 9.08) 3.03 (0.92 – 9.96) 
Model 3 1 (ref) 1.11 (0.33 – 3.80) 3.10 (0.98 – 9.82) 3.41 (1.02 – 11.5) 
Model 4 1 (ref) 0.92 (0.26 – 3.34) 1.95 (0.57 – 6.64) 1.23 (0.26 – 5.74) 
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